retatrutide triple agonist clinical trials Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Retatrutide Dosing Guide: 1-12 mg
Pay in 4 interest-free payments of $7.00 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12


















:max_bytes(150000):strip_icc()/Health-GettyImages-2200929852-cbe13f76512c4cd3b51252536927920f.jpg)






